与放射性碘治疗巴塞杜氏病相关的恶性肿瘤风险。

IF 2.7 3区医学 Q1 SURGERY

American journal of surgery Pub Date : 2024-11-06 DOI:10.1016/j.amjsurg.2024.116075

Sruthi Ramesh , Jason C. Fisher , Paige Curcio , Gary D. Rothberger , Jason Prescott , John Allendorf , Insoo Suh , Kepal N. Patel

{"title":"与放射性碘治疗巴塞杜氏病相关的恶性肿瘤风险。","authors":"Sruthi Ramesh , Jason C. Fisher , Paige Curcio , Gary D. Rothberger , Jason Prescott , John Allendorf , Insoo Suh , Kepal N. Patel","doi":"10.1016/j.amjsurg.2024.116075","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Radioactive iodine therapy (RAI) is a frequently chosen therapy for Graves' disease. The aim of this study was to determine whether RAI for Graves’ disease increases the risk of thyroid malignancy.</div></div><div><h3>Methods</h3><div>A retrospective analysis was performed of all Graves’ disease patients who underwent thyroidectomy at a single institution between 2013 and 2022. Comparative analyses were performed with cohorts based on RAI therapy as the primary grouping variable.</div></div><div><h3>Results</h3><div>413 patients were identified, of which 38 received RAI prior to surgery. RAI treated patients were more likely to undergo surgery for known malignancy or indeterminate nodules. RAI patients were also more likely to have malignancies larger than 1 cm. Among RAI treated patients, those who developed malignancy were older at the time of Graves’ diagnosis and received early RAI therapy.</div></div><div><h3>Conclusions</h3><div>Use of RAI for treatment of Graves’ disease increases the progression of thyroid carcinoma, but not the prevalence. Older age and early RAI therapy may be risk factors for malignancy in RAI treated patients.</div></div>","PeriodicalId":7771,"journal":{"name":"American journal of surgery","volume":"241 ","pages":"Article 116075"},"PeriodicalIF":2.7000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Malignancy risk associated with radioactive iodine therapy for Graves’ disease\",\"authors\":\"Sruthi Ramesh , Jason C. Fisher , Paige Curcio , Gary D. Rothberger , Jason Prescott , John Allendorf , Insoo Suh , Kepal N. Patel\",\"doi\":\"10.1016/j.amjsurg.2024.116075\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Radioactive iodine therapy (RAI) is a frequently chosen therapy for Graves' disease. The aim of this study was to determine whether RAI for Graves’ disease increases the risk of thyroid malignancy.</div></div><div><h3>Methods</h3><div>A retrospective analysis was performed of all Graves’ disease patients who underwent thyroidectomy at a single institution between 2013 and 2022. Comparative analyses were performed with cohorts based on RAI therapy as the primary grouping variable.</div></div><div><h3>Results</h3><div>413 patients were identified, of which 38 received RAI prior to surgery. RAI treated patients were more likely to undergo surgery for known malignancy or indeterminate nodules. RAI patients were also more likely to have malignancies larger than 1 cm. Among RAI treated patients, those who developed malignancy were older at the time of Graves’ diagnosis and received early RAI therapy.</div></div><div><h3>Conclusions</h3><div>Use of RAI for treatment of Graves’ disease increases the progression of thyroid carcinoma, but not the prevalence. Older age and early RAI therapy may be risk factors for malignancy in RAI treated patients.</div></div>\",\"PeriodicalId\":7771,\"journal\":{\"name\":\"American journal of surgery\",\"volume\":\"241 \",\"pages\":\"Article 116075\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0002961024006275\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of surgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002961024006275","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

摘要

背景：放射性碘治疗（RAI）是巴塞杜氏病的常用疗法。本研究旨在确定RAI治疗巴塞杜氏病是否会增加甲状腺恶性肿瘤的风险：对2013年至2022年间在一家机构接受甲状腺切除术的所有巴塞杜氏病患者进行了回顾性分析。以 RAI 治疗为主要分组变量的队列进行了比较分析：共发现413例患者，其中38例在手术前接受了RAI治疗。接受 RAI 治疗的患者更有可能因已知的恶性肿瘤或不确定的结节而接受手术。接受 RAI 治疗的患者也更有可能患有大于 1 厘米的恶性肿瘤。在接受RAI治疗的患者中，出现恶性肿瘤的患者在确诊为巴塞杜氏综合征时年龄较大，并且接受RAI治疗的时间较早：结论：使用RAI治疗巴塞杜氏病增加了甲状腺癌的进展，但并没有增加其发病率。年龄较大和早期接受RAI治疗可能是RAI治疗患者发生恶性肿瘤的危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Malignancy risk associated with radioactive iodine therapy for Graves’ disease

Background

Radioactive iodine therapy (RAI) is a frequently chosen therapy for Graves' disease. The aim of this study was to determine whether RAI for Graves’ disease increases the risk of thyroid malignancy.

Methods

A retrospective analysis was performed of all Graves’ disease patients who underwent thyroidectomy at a single institution between 2013 and 2022. Comparative analyses were performed with cohorts based on RAI therapy as the primary grouping variable.

Results

413 patients were identified, of which 38 received RAI prior to surgery. RAI treated patients were more likely to undergo surgery for known malignancy or indeterminate nodules. RAI patients were also more likely to have malignancies larger than 1 cm. Among RAI treated patients, those who developed malignancy were older at the time of Graves’ diagnosis and received early RAI therapy.

Conclusions

Use of RAI for treatment of Graves’ disease increases the progression of thyroid carcinoma, but not the prevalence. Older age and early RAI therapy may be risk factors for malignancy in RAI treated patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American journal of surgery 医学-外科

CiteScore

5.00

自引率

6.70%

发文量

570

审稿时长

56 days

期刊介绍： The American Journal of Surgery® is a peer-reviewed journal designed for the general surgeon who performs abdominal, cancer, vascular, head and neck, breast, colorectal, and other forms of surgery. AJS is the official journal of 7 major surgical societies* and publishes their official papers as well as independently submitted clinical studies, editorials, reviews, brief reports, correspondence and book reviews.